BOUSBIB ARI sold (to issuer) $12.2M of IQV

BOUSBIB ARI (See Remarks) sold (to issuer) 49,927 shares of IQVIA HOLDINGS INC. (IQV) at an average of $244.70 ($244.60–$247.00, $12.22M total) across 2 trades on 2026-07-29.

Original reporting
SEC EDGAR · BOUSBIB ARI
Published Jul 31, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IQV
Neutral
medium confidence
Mentioned
$IQV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

The disclosure provides a concrete insider activity datapoint (size, price range, and sale-to-issuer code) but does not introduce new fundamental information.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but the filing does not change IQVIA’s outlook.

03

What to watch

No 10b5-1 plan is indicated, so traders may scrutinize whether the sale was discretionary versus plan-driven, though the filing still lacks any stated rationale.

Relevance 7/10Novelty 5/10Timing: filed 2026-07-31, transaction dated 2026-07-29

Background

SEC Form 4 insider transaction for IQVIA Holdings Inc., reported by officer/director BOUSBIB ARI.

Company-level read

Ticker impact

$IQVNeutralMedium confidence
Context

IQVIA Form 4 shows officer/director BOUSBIB ARI sold 49,927 shares to the issuer for about $12.22M at $244.60 to $247.00 on 2026-07-29.

Expected impact

Likely limited near-term impact; any effect is more about interpreting insider behavior than new fundamentals.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure with transaction size and pricing, but it does not include new company guidance, operating results, or regulatory/legal developments.

Market effects

Minimal; this is company-specific insider transaction data with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the code is sale to issuer, the transaction may reflect routine buyback participation or pre-arranged mechanics rather than a negative view on IQVIA.

Key entities

  • IQVIA HOLDINGS INC.

    Company whose insider transaction is disclosed on SEC Form 4.

  • BOUSBIB ARI

    Officer and director reporting the sale to the issuer.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IQVHighAI 8/10

5 revealing analyst questions from IQVIA’s Q3 earnings call

IQVIA reported Q3 revenue of $4.43 billion, beating estimates by 1.5%, with adjusted EPS of $3.34, a 2% beat. The company raised full-year revenue guidance to $17.43 billion. Analysts discussed AI-driven workflows, margin improvements, and clinical bookings during the earnings call. CEO Ari Bousbib highlighted proprietary data and life sciences expertise as key differentiators.

$IQVMedAI 8/10

IQVIA Holdings Inc (IQV) (Q3 2026) Earnings Call Highlights: Record Bookings, Raised

IQVIA Holdings Inc. reported Q3 2026 earnings with record bookings and raised guidance. Revenue was $4.428B, up 8% YoY, and adjusted EBITDA rose 8.7%. Challenges include FX headwinds and R&D backlog adjustments. Management highlighted AI adoption and strong biotech demand. Full-year 2026 guidance was increased, with revenue expected between $17.35B-$17.5B. No 2027 guidance was provided.

$IQVHighAI 8/10

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA reported Q3 revenue growth of 6.9% to $1.79B, with organic growth at 4%. AI adoption contributed to commercial and clinical momentum, with 415 AI agents deployed. The company raised its 2026 outlook, expecting revenue of $17.35B-$17.50B and adjusted EPS of $12.90-$13.00. Cash flow from operations was $825M, with free cash flow at $667M.

$IQVHighAI 9/10

IQVIA (IQV) Q3 2026 Earnings Call Transcript

IQVIA reported Q3 2026 revenue of $4.43B, up 8%, with organic growth at 6%. Adjusted EBITDA grew 8.7% to $1.03B, and adjusted EPS rose 11.3% to $3.34. R&D solutions revenue increased 8.7%, and commercial solutions revenue grew 6.9%. The company raised full-year revenue guidance to $17.35B-$17.5B. AI deployments and emerging biopharma funding growth were highlighted.